STOCK TITAN

YS Biopharma Co Ltd - YS STOCK NEWS

Welcome to our dedicated news page for YS Biopharma Co (Ticker: YS), a resource for investors and traders seeking the latest updates and insights on YS Biopharma Co.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect YS Biopharma Co's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of YS Biopharma Co's position in the market.

Rhea-AI Summary
YS Biopharma Co., Ltd. (NASDAQ: YS) announces Noble Capital Markets' initiation of equity research coverage with an 'Outperform' rating and a 12-month price target of US$5.25 per share. The report highlights the PIKA Immunomodulating Platform, significant opportunities in the anti-viral and immuno-oncology markets, and the commercialized rabies vaccine. Noble's price target is based on FY2029 EPS of RMB6.93 ($0.95), discounted at 30% and applying a Nasdaq earnings multiple of 20x.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.14%
Tags
none
-
Rhea-AI Summary
YS Biopharma completes subject enrollment in Phase 3 clinical trial of PIKA Rabies Vaccine. The trial includes 4,500 subjects and aims to assess safety, immunogenicity, and lot-to-lot consistency. The vaccine utilizes proprietary PIKA adjuvant technology, showing strong immunogenicity in previous trials. The PIKA Rabies Vaccine has the potential to achieve accelerated protection and replace conventional regimens.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
-
Rhea-AI Summary
YS Biopharma has received a Deficiency Letter from Nasdaq, indicating that its closing bid price has been below $1.00 per share for the last 31 consecutive business days. The Company has a compliance period of 180 calendar days to regain compliance. If it fails to do so, it may be eligible for an additional 180 calendar days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15%
Tags
none
Rhea-AI Summary
YS Biopharma enrolls first subject in Phase 3 trial of PIKA Rabies Vaccine, expected to include 4,500 subjects. Previous trials show safety and strong immunogenicity. Potential to achieve best-in-class accelerated protection. Positive outlook for future vaccine interventions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.75%
Tags
-
Rhea-AI Summary
YS Biopharma receives patent for PIKA YS-HBV-002 vaccine for chronic HBV infection
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags
none
-
Rhea-AI Summary
YS Biopharma to participate in Citi's Biopharma Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.5%
Tags
conferences
Rhea-AI Summary
YS Biopharma's Founder and Chairperson, Mr. Yi Zhang, and CEO, Dr. Hui Shao, purchased 429,188 and 46,300 ordinary shares, respectively, on the open market. The investments reflect their belief in the company's long-term strategy and growth potential.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
60.46%
Tags
none
-
Rhea-AI Summary
YS Biopharma announces unaudited financial results for Q1 2024, with total revenues of RMB176.3 million and a gross profit margin of 80.3%. The company faced tight inventory levels due to COVID-related disruptions but took steps to enhance operations. Demand for YSJA rabies vaccine remains robust. YS Biopharma continues to advance its clinical pipeline, including PIKA rabies vaccine and PIKA recombinant COVID-19 vaccine. Balance sheet remains strong.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.09%
Tags
-
Rhea-AI Summary
YS Biopharma reports 36.3% YoY increase in total revenues, achieves 77.7% gross margin, and strengthens balance sheet. PIKA rabies vaccine approved for Phase III trials in Singapore, the Philippines, and Pakistan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.93%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
YS Biopharma Co Ltd

Nasdaq:YS

YS Rankings

YS Stock Data

161.96M
17.10M
81.43%
4.98%
0.05%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
China
Beijing